News of Note—Inovio-AstraZeneca HPV study, Changsheng and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Investigators have started a phase 2 study at MD Anderson Cancer Center to test MedImmune’s MEDI0457, which AstraZeneca licensed from Inovio, in combination with Imfinzi in HPV-related cancers. Release

> Chinese stock regulators have started delisting Changchun Changsheng Life Sciences from the Shenzhen Stock Exchange over a major vaccine scandal. Xinhua article

INDUSTRY RESEARCH

Veeva 2019 Unified Clinical Operations Survey

Share your thoughts in this quick survey. The first 50 qualified respondents will receive a $5 Amazon gift card, and, in appreciation for your time, all qualified survey respondents will be entered in a drawing to win a $50 Amazon gift card.

> Batavia Biosciences will help the International AIDS Vaccine Initiative to develop a Lassa fever vaccine under a grant from the Coalition for Epidemic Preparedness Innovations. Release